With increased CGM system accuracy and insulin pump systems integration, the path toward automated insulin delivery has also made incredible progress, allowing the development and study of multiple platforms and algorithms for closed loop systems. [13] [14] [15] Presently, various integrated CGM/insulin pump systems are commercially available. 16, 17 Similarly, several automated insulin delivery models are being investigated. [18] [19] [20] [21] It is reasonable to predict that the transition to fully automated insulin delivery systems could become a reality in the next 5 years.
However, despite these significant advances in diabetes technology, persistent barriers to widespread CGM adoption continue to exist. In the clinical setting, routine integration of personal or professional CGM has not been optimized. This article aims at reviewing the clinical benefits of professional and personal CGM and its application to daily practice; it also aims to analyze the role of the patient and practitioner as barriers to wider adoption. Finally, it suggests a simple, stepped approach to review and interpretation of CGM data, a potentially useful tool for clinicians regardless of CGM system brand or software used.
Methods
Search and review of the medical literature, societies' guidelines, consensus statements, professional experience, and endocrinology fellows training guided the preparation of this article. Detailed analysis of available CGM categories, their application in patients with diabetes, and the benefits and challenges of CGM integration in clinical practice were evaluated.
Results

Benefits of CGM Therapy
The clinical benefits of personal CGM use in patients with type 1 diabetes (T1DM) have been demonstrated in multiple clinical trials over the last decade. Reduction of HbA1c and hypoglycemia as well as glycemic variability is well established, regardless of the method of insulin therapy. 22 The 2016 CGM Consensus Conference publication from the American Association of Clinical Endocrinologists (AACE) states that CGM is likely to benefits any patient on intensive insulin therapy, regardless of the type of diabetes. 23 In 2016, None No § A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycemia or impending hypoglycemia is reported by the system or when symptoms do not match the system readings (reference). *2 calibrations/day. **4 calibrations/day.
the Endocrine Society Clinical Practice Guidelines on diabetes and technology recommended intermittent use of CGM for adult patients with type 2 diabetes (T2DM) (not on prandial insulin) with HbA1c ⩾7%, willing and able to use the device. 24 The reason for intermittent use was dictated by the fact that, at the time of publication, data for evidence using CGM in patients on MDI was not yet available. More recently, evidence of personal CGM benefits in patients with T2DM on intensive insulin therapy has been published, and reports of positive effects on glycemic control for T2DM patients not on insulin therapy are also increasing. [25] [26] [27] [28] CGM use improves diabetes-specific quality of life markers such as diabetes distress and hypoglycemic confidence, 29 and lowers adolescent and parent distress. 30 Similarly, economic benefits of CGM therapy have been reported with increased frequency, with decrease in total health care costs and hospital admissions.
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Role of Personal and Professional CGM in Clinical Practice
CGM use in clinical practice falls in two main categories, personal and professional. The characteristics of available CGM systems are outlined in Table 1 . Personal CGM systems, known as real-time (rt-CGM) or intermittently scanned (is-CGM) systems, record glucose every 5-15 minutes via a disposable or implantable sensor with life duration from 6 to 90 days, depending on manufacturer. The information is sent via a transmitter to a display device, either a dedicated reader or a smart phone App. While Medtronic (Northridge, CA), Dexcom (San Diego, CA) and Abbott (Alameda, CA) CGM systems use an enzymatic reaction with glucose oxidase as substrate, Senseonics (Germantown, MA) Eversense® CGM system uses a fluorescence sensing technology. Some CGM systems are used nonadjunctively and patients can make insulin dose decisions based on SG readings. This particular feature has decreased the frequency of SMBG and has been shown to be safe and effective 3 without worsening of glucose control. 33 CGM coverage is now available for Medicare beneficiaries 34, 35 and the most recent factory-calibrated CGM systems approval has virtually eliminated the need for confirmatory blood glucose levels by fingerstick. 9, 12 Professional CGM systems (diagnostic or retrospective CGM) are usually owned by practices and worn intermittently by patients in either a "blinded or "unblinded" fashion. Their features are outlined in Table 1 . Even though these tools are usually recommended mostly for patients with T1DM, 24, 36 in reality, any patient with diabetes presenting to the endocrinologist office could greatly benefit from wearing blinded or unblinded professional CGM. 37 Often the professional CGM sessions can be used as a "catalyst" for patients to move toward starting personal CGM therapy. In T2DM patients, professional CGM could have a great added value for the ability to "uncover" the presence of hypo-and hyperglycemia or hypoglycemia unawareness. It has been recently reported that patients with T2DM have significant fear of hypoglycemia or hypoglycemia unawareness, which may limit intensification of therapy to achieve glycemic goals. 38 For these patients, mostly on intensive insulin regimen, professional CGM could provide not only direct information of patients' "glycemic status," but also actionable interventions, whether pharmacological or educational, and facilitate personalized regimen changes. Evidence from randomized-controlled trials as well as observational studies indicate that professional CGM is beneficial for T2DM patients on various therapies. 26 Standards of care for diabetes and guidelines from professional societies recommend that all patients with T1DM and those with T2DM on intensive insulin therapy should be placed on therapeutic CGM (personal CGM) or use professional CGM intermittently. 23, 24, 39 As previously reported, 40 to maximize the benefits of professional CGM sessions in clinical practice, patients should be advised to keep a blood glucose log, as well as medication, food and activity diary. Documenting events that may contribute to changes in glucose levels such as physical activity, stressors, illness, menses, special events, is also advised.
In addition, scheduling the CGM procedure to include weekdays as well as weekends is very useful, so that information relative to variable schedule and its effects on glucose profiles can be captured. When setting up a professional CGM session, targeted therapeutic interventions can be made or new medications can be started; patients can use them for a portion of the procedure. This enables patients to promptly evaluate the effects of the new regimen on their glucose profiles upon review of CGM data with the clinician. If hypoglycemia unawareness is strongly suspected, unblinded professional CGM should be recommended, setting up hypoglycemia alerts accordingly and instructing patients on how to adequately treat hypoglycemic episodes should they occur during the procedure. Clear instructions should be given to the patient if frequent hypoglycemia below 55 mg/dL is noted during the procedure, so that immediate action can be taken to modify medication regimen prior to the end of the procedure.
While some argue that blinded CMG should no longer be used, 41 blinded CGM can still be used successfully in clinical practice. For example, in patients with T2DM with language or cognitive barriers who may be overwhelmed by the large amount of data generated by unblinded CGM, using FreeStyle Libre Pro system could provide great advantage in view of its simplicity of use and minimal training.
On the other hand, many patients are able to recognize overtime their glucose trends and patterns; for them, real-time CGM or unblinded professional CGM is undoubtedly a great tool. This process however takes time, would require pattern recognition training, and may or may not be accomplished within the limited time allowed for a professional unblinded CGM procedure. 
Benefits of Patient and Provider CGM Training in Clinical Practice
The use of personal CGM has been gradually increasing. However, despite the substantial evidence of clinical, patientrelated outcomes and cost -effectiveness benefits of CGM, the widespread adoption of CGM is still lacking. The T1D Exchange Registry Clinic Network has over 30,000 individuals with T1DM from over 80 clinics across the United States. In 2010-2012 they reported that only 7% of participants were using CGM. 42 In 2014 Wong et al reported that of 1662 CGM users for at least 1 year, 41% had discontinued using CGM. The three main reported reasons were discomfort (42%), problems with insertion (33%), or adhesion (30%). 43 Since 2012, the use of CGM in the T1D Exchange Registry has increased, with the largest uptake in the pediatric population. The most recent T1D Exchange Registry statistics report 30% CGM use in enrolled participants (2016) (2017) (2018) . 44 In addition, Abbott has recently reported that 800,000 people in 43 countries worldwide are using FreeStyle Flash Libre system. 12 Historically, known barriers have included perceived poor accuracy, cost, alarm fatigue and short duration of sensors. 43, 44 Although many of these barriers have been overcome with improved accuracy, increase in sensor duration, comfort of insertion and decreased need or elimination of calibration, challenges due to cost and reimbursement continue to remain a reality. Notably, there is increasing evidence suggesting that health care professionals' attitude toward CGM constitutes a barrier to CGM use expansion. 45 In addition, Tanenbaum et al 46 have reported a readiness chart for clinicians (MDs and CDEs) who are likely to prescribe diabetes technology tools. Three "clinician personas" were described, based on their readiness to promote CGM technology and comfort in keeping up with technology advances. Of these (n = 209) only 20% were "ready," while 41% fell in the category of "cautious" and 40% were "not yet ready." These data emphasize how clinicians may benefit from tailored training, as well as additional resources to help expanding the use of CGM therapy in clinical practice.
Therefore, provider and patient education is crucial. To achieve the full benefits of CGM therapy, patients need adequate training, such as understanding insertion techniques, and calibration techniques for the systems that still require it, reviewing frequency and optimal timing of calibrations. CGM use on a nearly daily basis and active participation with data review or reports notifications should be encouraged. Setting alerts and alarms should be done in stages. To avoid alarm fatigue, it may be prudent to set-up only hypoglycemia alerts upon training and postpone hyperglycemia alerts set-up to a later time, based on individual patient needs. Alternatively, wide thresholds should be considered (70-250 mg/dL) as suggested previously. 47 For patients without history of hypoglycemia unawareness, who are concerned about alarm fatigue, Abbott's FreeStyle Flash Libre offers a viable solution in that it only alerts the users when they scan the reader over the sensor/transmitter unit. Advanced training should also be offered to patients after several weeks of CGM use to include predictive alerts, recognition of patterns and trends as well as setting up trend arrows-based insulin dose adjustments. Of note, available CGM systems have different rate of change trend arrows meaning (see Table 2 ). To avoid confusion and dosing errors, education should be focused to the specific system patients are using.
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Discussion
Optimal integration of CGM technology in clinical practice presents multiple challenges for providers. Whether dealing with professional or personal CGM systems, clinicians are faced with the need to become familiar with several brand-specific software programs and reports. Although there are efforts toward standardization of CGM review and interpretation, 51 there are no systematic, standardized approaches, nor formal "CGM education courses" available to providers. Further challenges include the need for ancillary staff to upload CGM and/ or pump systems, and the time to sift through multiple reports from which to gather meaningful information and implement regimen changes for patients within the often-restricted time of an office visit.
The development of the ambulatory glucose profile (AGP) has been a fundamental initial step to standardize CGM data reporting tools. The AGP combines input from multiple days displaying CGM data into a single 24-hour period of time. It is one of the most helpful reports for the provider and a great place to start the CGM review. Initially developed by Mazze et al, 52 this report has been adopted by various platforms, including Dexcom CLARITY®, Diasend®-Glooko, Tidepool®, LibreView® and Medtronic CareLink™ and is recommended as the standard for visualization of CGM data. 51 The use of AGP in clinical practice, with modification of work flow to include printing of AGP report before rooming the patient, has been shown to reduce visits time in two centers. 53 Ideally, at least 14 days of data should be reviewed, as this has been shown to provide a good estimate of glycemic values for a 3-month period. 54 The AGP has multiple components, each of them contributing to gather information on the patient glycemic status at the time of the visit. Review of 14 days with CGM use of at least 70% are the first steps to ensure adequacy of data. SG average, coefficient of variation (CV), and standard deviation (SD) should follow. The CV is a measure of glycemic variability (GV), and an important element to review, as increased variability is associated with increased risk of hypoglycemic events. 55, 56 GV has also been the focus of numerous studies and has been associated to increased risk for diabetes complications, cognitive function, and quality of life. 51 When reviewing CGM data, it is critical to encourage the patient to aim for the highest percentage of glucose levels in target range (or Time in Range, TIR) of 70-180 mg/dL with very low percentage of time spent in hypoglycemia (Figure 1) . Achievement of high percentage spent in target range should be a process, and individual targets should be established with patients. Hypoglycemia definition has been revised 57 and in the AGP particular attention should be given to the percentage of time spent in level 1 or level 2 hypoglycemia (<70 mg/dL and <54 mg/dL, respectively). Hyperglycemia has also been redefined to includes level 1 and level 2 (>180 mg/dL and >250 mg/dL, respectively). Identification of episodes of level 2 hypoglycemia of any duration require immediate action during CGM review. Although there is no available clinical trial assessing the optimal percentage of time to spend in target range, hypo or hyperglycemia, it is reasonable to consider using the targets achieved with the most advanced insulin delivery/CGM technology, the hybrid-closed loop. 58 In the pivotal study participants achieved on average 72% TIR, with <3% in hypoglycemia and <25% in hyperglycemia. TIR and HbA1c are also highly correlated, and TIR of ~70% corresponds to an HbA1c of ~7%. 59 Review of daily views reports, whether for CGM alone or in combination with insulin pump data, is paramount (see Figures 2 and 3 ), as they allow for more granular information, so that glycemic fluctuations can be correlated to specific causes. Recurring patterns of hypo/hyperglycemia should be reviewed, and focus should be directed to the duration of each episode, especially hypoglycemia. Time spent in hyperglycemia, fasting, as well as from postprandial glycemic excursions should be reviewed next, and interventions made to adjust therapy as needed, whether related to basal insulin (or basal rates if using insulin pump therapy), mealtime insulin doses, or insulin sensitivity factor. Lifestyle effects on glucose levels such as physical activity, meal quality, and alcohol use should be reviewed and discussed. Also, effects of excessive insulin pump suspension time or insulin pump site failure should be identified and discussed to optimize insulin pump use. Finally, CGM alerts settings should be reviewed and individualized, so that alarm fatigue is avoided or minimized. A proposed stepped method to facilitate meaningful interpretation of CGM data is described in Table 3 . 
Conclusion
CGM therapy has transformed the care of diabetes in the last decade, and its benefits could extend to any patient with diabetes regardless of the type of pharmacological therapy. With factory-calibrated sensors, CGM may replace the need for SMBG in the near future. However, patient and provider CGM uptake is still limited, and standardized CGM interpretation protocols are lacking. Tailored education for patients and clinicians for their respective needs may be the key to expanded use of CGM in clinical practice. This article proposes suggestions for streamlined patient education and a stepped approach to CGM interpretation for the clinicians. Formal studies and validation of CGM interpretation protocols are needed to develop "best practices" for CGM integration in clinical practice.
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